Showing results (201-210 of 364) with videos related to

Sort By:
Pageof 37
Blood|December 26, 2008
Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemiaHui Yang, Tapan Kadia, Lianchun Xiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264A P Venook, M J Egorin, G L Rosner, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|March 1, 1992
Phase III evaluation of doxorubicin and whole-body hyperthermia in dogs with lymphomaR L Page, D W Macy, G K Ogilvie, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B studyR A Fleming, R L Capizzi, G L Rosner, et al.
Cancers|December 18, 2019
Analysis of PMEPA1 Isoforms (a and b) as Selective Inhibitors of Androgen and TGF-β Signaling Reveals Distinct Biological and Prognostic Features in Prostate CancerShashwat Sharad, Zsófia M Sztupinszki, Yongmei Chen, et al.
The Canadian Journal of Urology|August 31, 2019
A prospective study of health-related quality of life outcomes among men treated for intermediate- and high-risk prostate cancer: the impact of primary and secondary therapiesMazen Alsinnawi, Jennifer Cullen, Lauren M Hurwitz, et al.
Drug Safety|May 24, 2020
Information Visualization Platform for Postmarket Surveillance Decision SupportJonathan Spiker, Kory Kreimeyer, Oanh Dang, et al.
Blood|February 1, 2007
Ancestry and pharmacogenetics of antileukemic drug toxicityShinji Kishi, Cheng Cheng, Deborah French, et al.
Cancers|March 4, 2026
RETRACTED: Sharad et al. Analysis of PMEPA1 Isoforms (a and b) as Selective Inhibitors of Androgen and TGF-β Signaling Reveals Distinct Biological and Prognostic Features in Prostate Cancer. Cancers 2019, 11, 1995Shashwat Sharad, Zsófia M Sztupinszki, Yongmei Chen, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|July 27, 2001
A phase II trial testing the thermal dose parameter CEM43 degrees T90 as a predictor of response in soft tissue sarcomas treated with pre-operative thermoradiotherapyP D Maguire, T V Samulski, L R Prosnitz, et al.
Pageof 37